Latest Biotech News

EpiBiologics closed a $107 million Series B to advance its EpiTAC protein‑degrader antibody platform and prepare its lead candidate EPI‑326 for first‑in‑human testing. The Bay Area company...

AirNexis Therapeutics raised $200 million in a Series A and acquired exclusive outside‑China rights to Haisco’s PDE3/4 inhibitor for COPD, funding development of AN01. The deal structure includes...

Alveus Therapeutics emerged with a $159.8 million Series A to advance an obesity program designed to mirror tirzepatide’s multimodal efficacy with potential dosing advantages. The company’s...

Krystal Biotech disclosed early clinical proof‑of‑concept data for a mutation‑agnostic gene therapy approach in cystic fibrosis and said it plans to pursue a pivotal development path. The company...

Aktis Oncology priced an upsized US IPO that raised $318 million, signaling renewed investor appetite for radiopharmaceutical platforms. The Boston-based developer sold 17.65 million shares at $18...

Eli Lilly agreed to acquire Ventyx Biosciences for $1.2 billion in cash, paying $14 per share, to add oral NLRP3 inhibitors to its inflammation pipeline. Lilly positioned the buyout as a strategic...

Parabilis Medicines closed a $305 million Series F to advance its Helicon peptide platform aimed at intracellular and previously 'undruggable' targets. The funding, led by major crossover and...

Protein‑degrader startup EpiBiologics raised $107 million in a Series B to advance EPI‑326, a bispecific degrader targeting oncogenic surface proteins, into first‑in‑human studies. The financing...

Aurora Therapeutics — cofounded and advised by gene‑editing pioneers including Jennifer Doudna and Fyodor Urnov — launched with seed backing to scale bespoke CRISPR therapies for ultra‑rare...

Illumina appointed Eric Green, former director of the National Human Genome Research Institute, as chief medical officer starting Feb. 2. The hire signals Illumina’s push to deepen clinical and...

Boltz, a public benefit corporation spun out of MIT CSAIL, launched with $28 million in seed funding to make high‑accuracy open AI models for molecular structure prediction and therapeutic design...

Pfizer entered a research collaboration with Gordian Bio to apply Gordian’s in vivo mosaic screening platform to prioritize obesity targets directly in visceral adipose tissue. The collaboration...

Krystal Biotech disclosed early clinical signals for a mutation‑agnostic approach to cystic fibrosis, reporting data that the company says support a direct move into a pivotal trial. The firm...

The Biotechnology Innovation Organization (BIO) launched the BIO Investment Council to strengthen ties between investors and early‑stage biotechs and to improve private capital formation. The...

Aktis Oncology priced its initial public offering, raising $318 million in what market watchers called the first meaningful biotech IPO of 2026. The upsized offering was led in part by a $100...

Eli Lilly agreed to acquire Ventyx Biosciences for about $1.2 billion in cash to add oral NLRP3 inhibitors to its inflammation pipeline. The deal gives Lilly clinical‑stage assets targeting the...

Media reports say Merck is in discussions to acquire Revolution Medicines in a transaction valued between $28 billion and $32 billion. Sources cited by the Financial Times indicated negotiations...

Illumina appointed former NHGRI director Eric Green as chief medical officer, effective Feb. 2. Green leaves a long public‑sector tenure to join the sequencing leader as it seeks to accelerate...

Boltz launched as a public benefit corporation out of MIT CSAIL with a $28 million seed round led by Amplify, a16z and Zetta, aiming to make high‑accuracy AI models and drug‑design tools broadly...

A startup co‑founded by gene‑editing experts including Fyodor Urnov, with advisory support from Jennifer Doudna, launched Aurora Therapeutics after a $16 million seed from Menlo Ventures. The...